Seroprevalence of antibodies to SARS-CoV-2 among blood donors in the early months of the pandemic in Saudi Arabia

Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved..

BACKGROUND: Serologic testing provides better understanding of SARS-CoV-2 prevalence and its transmission. This study was an investigation of the prevalence of antibodies to SARS-CoV-2 among blood donors in Saudi Arabia.

OBJECTIVE: To estimate the seroprevalence of anti-SARS-CoV-2 antibodies among blood donors in Saudi Arabia during the early phase of the COVID-19 pandemic.

METHODS: Serology results and epidemiological data were analyzed for 837 adult blood donors, with no confirmed SARS-CoV-2 infection, in Saudi Arabia from 20th to 25th May 2020. Seroprevalence was determined using electrochemical immunoassay to detect anti-SARS-CoV-2 antibodies.

RESULTS: The overall seroprevalence of anti-SARS-CoV-2 antibodies was 1.4% (12/837). Non-citizens had higher seroprevalence compared with citizens (OR 13.6, p = 0.001). Secondary education was significantly associated with higher seroprevalence compared with higher education (OR 6.8, p = 0.005). The data showed that the highest seroprevalence was in Makkah (8.1%). Uisng Makkah seroprevalence as the reference, the seroprevalence in other areas was: Madinah 4.1% (OR 0.48, 95% CI 0.12-1.94), Jeddah 2.3% (OR 0.27, 95% CI 0.31-2.25), and Qassim 2.9 % (OR 0.34, 95% CI 0.04-2.89) and these were not statistically different from seroprevalence in the Makkah region.

CONCLUSIONS: At the early months of the COVID-19 pandemic in Saudi Arabia, the seroprevalence of antibodies to SARS-CoV-2 among blood donors was low, but was higher among non-citizens. These findings may indicate that non-citizens and less educated individuals may be less attentive to preventive measures. Monitoring seroprevalence trends over time require repeated sampling.

Medienart:

E-Artikel

Erscheinungsjahr:

2021

Erschienen:

2021

Enthalten in:

Zur Gesamtaufnahme - volume:104

Enthalten in:

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases - 104(2021) vom: 25. März, Seite 452-457

Sprache:

Englisch

Beteiligte Personen:

Banjar, Ayman [VerfasserIn]
Al-Tawfiq, Jaffar A [VerfasserIn]
Alruwaily, Amaal [VerfasserIn]
Alserehi, Haleema [VerfasserIn]
Al-Qunaibet, Ada [VerfasserIn]
Alaswad, Rehab [VerfasserIn]
Almutlaq, Hind [VerfasserIn]
Almudaiheem, Abdullah [VerfasserIn]
Khojah, Abdullah T [VerfasserIn]
Alsaif, Faisal [VerfasserIn]
Almolad, Shaza Karim [VerfasserIn]
Alqahtani, Saeed [VerfasserIn]
AlJurayyan, Abdullah [VerfasserIn]
Alotaibi, Abdullah [VerfasserIn]
Almalki, Safar [VerfasserIn]
Abuhaimed, Yousef [VerfasserIn]
Alkhashan, Abdullah [VerfasserIn]
Alfaifi, Amal [VerfasserIn]
Alabdulkareem, Khaled [VerfasserIn]
Jokhdar, Hani [VerfasserIn]
Assiri, Abdullah [VerfasserIn]
Almudarra, Sami [VerfasserIn]

Links:

Volltext

Themen:

Antibodies, Viral
Blood donors
COVID-19
IgG antibody
Immunoglobulin G
Journal Article
SARS-CoV-2
Serology
Seroprevalence

Anmerkungen:

Date Completed 23.04.2021

Date Revised 10.11.2023

published: Print-Electronic

Citation Status MEDLINE

doi:

10.1016/j.ijid.2021.01.028

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM320279154